Theodora Anagnostou, MD
Hematology & Oncology · New York, NYNPI 1780026567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,943 of the $10,304 with a category attached, or 77.1%. Ipsen Biopharmaceuticals, Inc accounts for 64.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $7,226 and has fallen 95.8% since, to $301 in 2025.
Across 33 payments — averaging $312.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$7K
- Genmab U.S., Inc.$2K
- Janssen Scientific Affairs, LLC$309
- Dr.reddy's Laboratories,inc.$260
- AbbVie$252
- Sanofi$208
- plus $936 from 13 others
Across 39 payments — averaging $6765.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$138K
- Seagen Inc.$97K
- Pfizer$29K
What the payments were for
- Consulting fees$2603%
- Speaking & faculty fees$7,94377%
- Travel & lodging$1181%
- Food & beverage$1,98419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 2 | $6,654 |
| Genmab U.S., Inc. | 6 | $1,686 |
| Janssen Scientific Affairs, LLC | 3 | $309 |
| Dr.reddy's Laboratories,inc. | 1 | $260 |
| AbbVie | 2 | $252 |
| Sanofi | 2 | $208 |
| Seagen Inc. | 2 | $206 |
| TG Therapeutics, Inc. | 1 | $137 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $129 |
| AstraZeneca | 1 | $125 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 2 | $54 |
| Sanofi-aventis U.S. LLC | 1 | $51 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Astellas Pharma US Inc | 1 | $33 |
| Amgen | 1 | $33 |
| Bristol Myers Squibb | 1 | $29 |
| Merck | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,304 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.